116 related articles for article (PubMed ID: 15937032)
21. [Expression of cyclooxygenase-2 and urokinase plasminogen activator in gastric carcinoma and the clinical significance thereof].
Zhang FH; Zhou YN; Li GZ; Li Q; Lu B; Zhang ZY; Wu ZQ; Fan P; Hao TJ
Zhonghua Yi Xue Za Zhi; 2008 Dec; 88(46):3279-82. PubMed ID: 19159555
[TBL] [Abstract][Full Text] [Related]
22. [Urokinase-type plasminogen activator (uPA), uPA receptor (uPA-R) and inhibitors (PA I -1) expression in hepatocellular carcinoma in relation to cancer invasion/metastasis and prognosis].
Zheng Q; Tang Z; Wu Z
Zhonghua Zhong Liu Za Zhi; 1998 Jan; 20(1):57-9. PubMed ID: 10921061
[TBL] [Abstract][Full Text] [Related]
23. Significant down-regulation of the plasminogen activator inhibitor 1 mRNA in pancreatic cancer.
Warnecke-Eberz U; Prenzel KL; Baldus SE; Metzger R; Dienes HP; Bollschweiler E; Hoelscher AH; Schneider PM
Pancreas; 2008 Mar; 36(2):173-7. PubMed ID: 18376309
[TBL] [Abstract][Full Text] [Related]
24. Expression of urokinase-type plasminogen activator, urokinase-type plasminogen activator receptor and plasminogen activator inhibitors in patients with renal cell carcinoma: correlation with tumor associated macrophage and prognosis.
Ohba K; Miyata Y; Kanda S; Koga S; Hayashi T; Kanetake H
J Urol; 2005 Aug; 174(2):461-5. PubMed ID: 16006865
[TBL] [Abstract][Full Text] [Related]
25. Urokinase-type plasminogen activator is a marker of aggressive phenotype and an independent prognostic factor in mismatch repair-proficient colorectal cancer.
Minoo P; Baker K; Baumhoer D; Terracciano L; Lugli A; Zlobec I
Hum Pathol; 2010 Jan; 41(1):70-8. PubMed ID: 19740518
[TBL] [Abstract][Full Text] [Related]
26. Epithelial-mesenchymal transition (EMT) and activated extracellular signal-regulated kinase (p-Erk) in surgically resected pancreatic cancer.
Javle MM; Gibbs JF; Iwata KK; Pak Y; Rutledge P; Yu J; Black JD; Tan D; Khoury T
Ann Surg Oncol; 2007 Dec; 14(12):3527-33. PubMed ID: 17879119
[TBL] [Abstract][Full Text] [Related]
27. Urokinase-type plasminogen activator and plasminogen-activator-inhibitor type 1 predict metastases in good prognosis breast cancer patients.
De Cremoux P; Grandin L; Diéras V; Savignoni A; Degeorges A; Salmon R; Bollet MA; Reyal F; Sigal-Zafrani B; Vincent-Salomon A; Sastre-Garau X; Magdelénat H; Mignot L; Fourquet A;
Anticancer Res; 2009 May; 29(5):1475-82. PubMed ID: 19443353
[TBL] [Abstract][Full Text] [Related]
28. Low-level expression of Smad7 correlates with lymph node metastasis and poor prognosis in patients with pancreatic cancer.
Wang P; Fan J; Chen Z; Meng ZQ; Luo JM; Lin JH; Zhou ZH; Chen H; Wang K; Xu ZD; Liu LM
Ann Surg Oncol; 2009 Apr; 16(4):826-35. PubMed ID: 19165547
[TBL] [Abstract][Full Text] [Related]
29. Analysis of the invasion-metastasis mechanism in pancreatic cancer: involvement of plasmin(ogen) cascade proteins in the invasion of pancreatic cancer cells.
Tan X; Egami H; Nozawa F; Abe M; Baba H
Int J Oncol; 2006 Feb; 28(2):369-74. PubMed ID: 16391791
[TBL] [Abstract][Full Text] [Related]
30. Prognostic significance of dysadherin expression in patients with non-small cell lung cancer.
Tamura M; Ohta Y; Tsunezuka Y; Matsumoto I; Kawakami K; Oda M; Watanabe G
J Thorac Cardiovasc Surg; 2005 Sep; 130(3):740-5. PubMed ID: 16153922
[TBL] [Abstract][Full Text] [Related]
31. E-cadherin and urokinase-type plasminogen activator tissue status in gastric carcinoma.
Yonemura Y; Nojima N; Kaji M; Fujimura T; Itoh H; Ninomiya I; Miyazaki I; Endo Y; Sasaki T
Cancer; 1995 Sep; 76(6):941-53. PubMed ID: 8625219
[TBL] [Abstract][Full Text] [Related]
32. [Prognostic value of E-cadherin, CD34 in the patients with hepatocellular carcinoma].
Wu LQ; Lu Y; Lu HJ; Zhang B; Yang JY; Ma X
Zhonghua Wai Ke Za Zhi; 2006 Jun; 44(11):774-7. PubMed ID: 16836930
[TBL] [Abstract][Full Text] [Related]
33. Prognostic significance of the immediate early response gene X-1 (IEX-1) expression in pancreatic cancer.
Sasada T; Azuma K; Hirai T; Hashida H; Kanai M; Yanagawa T; Takabayashi A
Ann Surg Oncol; 2008 Feb; 15(2):609-17. PubMed ID: 18026799
[TBL] [Abstract][Full Text] [Related]
34. The expression of E-cadherin at the invasive tumor front of oral squamous cell carcinoma: immunohistochemical and RT-PCR analysis with clinicopathological correlation.
Wang X; Zhang J; Fan M; Zhou Q; Deng H; Aisharif MJ; Chen X
Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2009 Apr; 107(4):547-54. PubMed ID: 19327640
[TBL] [Abstract][Full Text] [Related]
35. Targeting of urokinase plasminogen activator receptor in human pancreatic carcinoma cells inhibits c-Met- and insulin-like growth factor-I receptor-mediated migration and invasion and orthotopic tumor growth in mice.
Bauer TW; Liu W; Fan F; Camp ER; Yang A; Somcio RJ; Bucana CD; Callahan J; Parry GC; Evans DB; Boyd DD; Mazar AP; Ellis LM
Cancer Res; 2005 Sep; 65(17):7775-81. PubMed ID: 16140945
[TBL] [Abstract][Full Text] [Related]
36. Survivin expression is a prognostic marker in pancreatic cancer patients.
Kami K; Doi R; Koizumi M; Toyoda E; Mori T; Ito D; Fujimoto K; Wada M; Miyatake S; Imamura M
Surgery; 2004 Aug; 136(2):443-8. PubMed ID: 15300213
[TBL] [Abstract][Full Text] [Related]
37. Quantitative RT-PCR assays for the determination of urokinase-type plasminogen activator and plasminogen activator inhibitor type 1 mRNA in primary tumor tissue of breast cancer patients: comparison to antigen quantification by ELISA.
Biermann JC; Holzscheiter L; Kotzsch M; Luther T; Kiechle-Bahat M; Sweep FC; Span PN; Schmitt M; Magdolen V
Int J Mol Med; 2008 Feb; 21(2):251-9. PubMed ID: 18204793
[TBL] [Abstract][Full Text] [Related]
38. Urokinase-plasminogen-activator receptor expression in disseminated tumour cells in the bone marrow and peripheral blood of patients with clinically localized prostate cancer.
Thomas C; Wiesner C; Melchior SW; Schmidt F; Gillitzer R; Thüroff JW; Pfitzenmaier J
BJU Int; 2009 Jul; 104(1):29-34. PubMed ID: 19154451
[TBL] [Abstract][Full Text] [Related]
39. Expression of E-cadherin, P-cadherin and N-cadherin in oral squamous cell carcinoma: correlation with the clinicopathologic features and patient outcome.
Pyo SW; Hashimoto M; Kim YS; Kim CH; Lee SH; Johnson KR; Wheelock MJ; Park JU
J Craniomaxillofac Surg; 2007 Jan; 35(1):1-9. PubMed ID: 17296306
[TBL] [Abstract][Full Text] [Related]
40. L1 expression as a marker for poor prognosis, tumor progression, and short survival in patients with colorectal cancer.
Boo YJ; Park JM; Kim J; Chae YS; Min BW; Um JW; Moon HY
Ann Surg Oncol; 2007 May; 14(5):1703-11. PubMed ID: 17211730
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
